In the case of STK19, basic misconceptions unfortunately led the field to believe that STK19 represents a great opportunity to develop targeted therapies for aggressive melanoma, with two separate studies reporting progress in producing small molecule inhibitors.11,13 Our analysis thus also underscores the importance of carefully analyzing newly discovered cancer drivers before resources are dedicated to therapy development. Here, WHR1 is linked to melanoma.